

## PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: **Mail Stop ISSUE FEE**  
**Commissioner for Patents**  
**P.O. Box 1450**  
**Alexandria, Virginia 22313-1450**  
 or **Fax** (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

34313 7390 02/09/2006

**ORRICK, HERRINGTON & SUTCLIFFE, LLP**  
**IP PROSECUTION DEPARTMENT**  
**4 PARK PLAZA**  
**SUITE 1600**  
**IRVINE, CA 92614-2558**

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

## Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

**Karen Johnson**

(Depositor's name)

*Karen Johnson*

(Signature)

**April 28, 2006**

(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/17,876	11/18/2000	John E. Edwards JR.	259/064	7636

TITLE OF INVENTION: PHARMACEUTICAL COMPOSITIONS AND METHODS TO VACCINATE AGAINST DISSEMINATED CANDIDIASIS

APPLN. TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	YES	\$700	\$0	\$700	05/09/2006

EXAMINER	ART UNIT	CLASS-SUBCLASS
----------	----------	----------------

DEVI, SARVAMANGALA J N

1645

424-274100

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363):
- ☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.
- ☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 02-02 or more recent) attached. Use of a Customer Number is required.
2. For printing on the patent front page, list **Orrick, Herrington & Sutcliffe LLP**
- (1) the names of up to 3 registered patent attorneys or agents OR, alternatively,
- (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

## 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE

(B) RESIDENCE: (CITY AND STATE OR COUNTRY)

Los Angeles Biomedical

Torrance, California 90502-2064

Research Institute at Harbor-UCLA Medical Center

Please check the appropriate assignee category or categories (will not be printed on the patent): ☒ Individual ☐ Corporation or other private group entity ☐ Government

## 4a. The following fee(s) are enclosed:

- ☒ Issue Fee
- ☐ Publication Fee (No small entity discount permitted)
- ☒ Advance Order - # of Copies **3**

## 4b. Payment of Fee(s):

- ☐ A check in the amount of the fee(s) is enclosed.
- ☐ Payment by credit card. Form PTO-2038 is attached.
- ☒ The Director is hereby authorized to charge the required fee(s), or credit any overpayment, to Deposit Account Number **15-0665** (enclose an extra copy of this form).

## 5. Change in Entity Status (from status indicated above)

- ☐ Applicant claims SMALL ENTITY status. See 37 CFR 1.27. ☐ Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).

The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above.

NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.

Authorized Signature

*David E. Wang*

Date

**04/28/2006**

Typed or printed name

**David E. Wang**

Registration No.

**38,358**

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/715,876	11/18/2000	John E. Edwards JR.	259/064	7636

34313 7590 02/02/2006

ORRICK, HERRINGTON & SUTCLIFFE, LLP  
IP PROSECUTION DEPARTMENT  
4 PARK PLAZA  
SUITE 1600  
IRVINE, CA 92614-2558

EXAMINER

DEVI, SARVAMANGALA J N

ART UNIT

PAPER NUMBER

1645

DATE MAILED: 02/02/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

PLEASE NOTE  
CHANGE IN  
INVENTOR  
INFO



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450  
www.uspto.gov

DECISION ON PETITION

In re Application of:

Edwards *et al.*

27 January 2006

Serial No. 09/715,876

Filed: 11/18/2000

For: Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis.

This is a decision in response to Applicants' request to correct inventorship filed 12/29/05 under 37 C.F.R. 1.48(a), by adding the name of Bradley J. Spellberg as an inventor and deleting the name of Jim Cutler as an inventor. The papers filed with the petition comprise: (a) Individual declarations by the co-inventors, John E. Edwards, Jr., Scott G. Filler, Yue Fu, Ashraf S. Ibrahim and Donald C. Sheppard; (b) A declaration by Jim Cutler stating that he is not the inventor of the instant application; (c) A declaration by Bradley J. Spellberg stating that he is an inventor of the instant application; (d) Statements by each of the inventor declaring that the error in failing to include the name of Bradley J. Spellberg and in adding the name of Jim Cutler as an inventor was without deceptive intent; (d) A consent by the assignee, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center to this change of inventorship pursuant to 37 C.F.R. 1.48(a) and 3.73(b); and (e) A fee as per 37 C.F.R. 1.17(i).

In light of various declarations and papers filed by the Applicants in compliance of 37 C.F.R. 1.48(a), the petition is hereby granted.

PETITION GRANTED.

*S. Devi*  
S. Devi, MS, Ph.D.

Primary Examiner

Air Unit 1645

Technology Center 1600